Zachary Klaassen speaks with Adrien Holzgreve about the FLEX-MRT trial, which aims to personalize lutetium-177 PSMA radioligand therapy delivery. Currently, Pluvicto™ follows fixed dosing from the ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the clinical value of the PROSTest to detect biochemical recurrence in ...

SNMMI annual meeting featured a clinical diagnosis and therapy session and a presentation by Dr. Kambiz Rahbar discussing the utility of the PROSTest to predict response to 177 Lu-PSMA therapy in ...

International guidelines present discrepancies concerning restaging transurethral resection (TURBT) for high-grade (HG) Ta bladder cancer. Recent studies with heterogeneous inclusion criteria have ...

This study aims to identify the optimal treatment strategy and conduct a prognostic analysis for patients with locally advanced Upper Tract Urothelial Carcinoma (UTUC).The study included 3,829 ...

The IMPACT-RCC study 7 evaluated visualization of clear cell RCC lesions in 42 patients with metastatic disease (n = 449 lesions). Patients in this study had a lesion size cutoff of 1 cm (lymph nodes ...

Dr. Abhilash Moolupuri presented the initial exploratory and phase I/II results of a trial evaluating a novel PSMA-targeting ...

In one patient, total body scans were performed at 15 minutes, 1 hour, 2 hours, and 4 hours post-injection. The effective dose was 0.022 mSv/MBq, with the stomach wall receiving the highest organ dose ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Huipan Liu ...

(UroToday.com) The 2025 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting held in New Orleans, LA, was host to an Oncology Discovery and Translational session. Dr. Gary Ulaner ...

Photocure, Use of photodynamic diagnosis (PDD), progression rates in NMIBC, mportance of BLC in bladder cancer care.

Anexelokto (AXL) protein and its ligand, growth arrest specific-6 (GAS6), are important drivers of metastasis in patients with advanced clear cell renal cell carcinoma (ccRCC). Batiraxcept ...